Overview

• The company will scale production through partnerships with local contract manufacturers in India, with specific partners, capacities and start dates not yet disclosed.
• A new manufacturing and quality hub in Hyderabad will oversee the contract network nationwide, with immediate hiring for engineers, chemists, analytical scientists, and quality professionals.
• Lilly says the collaborations aim to increase global availability of treatments for obesity and diabetes as well as Alzheimer’s, cancer and autoimmune diseases.
• The move extends a multiyear global buildout exceeding $55 billion, including a $5 billion Virginia facility under a $27 billion U.S. expansion plan, and follows the U.S. imposition of a 100% tariff on imported branded drugs.
• Telangana officials welcomed the investment, citing skilled talent and infrastructure in Hyderabad, where Lilly already maintains operations alongside sites in Gurugram and Bengaluru.